<DOC>
	<DOCNO>NCT02324673</DOCNO>
	<brief_summary>This Phase 1/2 , open-label , trial design ass pharmacokinetics , safety , tolerability , preliminary efficacy 3 multiple ascend dos Cannabidiol Oral Solution sequential fashion . Participants pediatric ( age 1-17 , inclusive ) , experience treatment-resistant seizure , satisfy inclusion/exclusion criterion .</brief_summary>
	<brief_title>Cannabidiol Oral Solution Pediatric Subjects With Treatment- Resistant Seizure Disorders</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Meets protocolspecified criterion qualification contraception , include treatmentresistant seizure disorder Is able speak understand language study conduct , able understand procedure study requirement voluntarily sign date informed consent form approve Institutional Review Board conduct study procedure In opinion Investigator , participant parent ( ) /caregiver ( ) willing able comply study procedure visit schedule , include venipuncture , inpatient stay study center , dose study center twice day need outpatient ) , Followup Visits ( applicable ) Subject parent ( ) /caregiver ( ) daily commitment study duration would interfere attend study visit History current use dietary supplement , drug overthe counter medication outside protocolspecified parameter Signs , symptoms history condition , per protocol opinion investigator , might compromise : 1. safety wellbeing participant study staff 2. safety wellbeing participant 's offspring ( pregnancy breastfeed ) 3. analysis result</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Treatment-resistant seizure</keyword>
</DOC>